AI-generated research brief — verify at source
Hospital-Based Multifaceted Intervention More Than Doubles Guideline Adherence in Heart Failure Patients
A randomised controlled trial found that a structured, hospital-initiated intervention more than doubled the proportion of heart failure patients achieving adherence to five guideline-recommended treatments at six months compared to usual care (61.8% vs. 28.7%; OR 6.27, 95% CI 3.35–11.76). The effect size was large and statistically robust, suggesting that the gap between guideline recommendations and real-world primary care practice can be meaningfully narrowed through coordinated transitional care.
What Was Studied
The trial investigated whether a multifaceted, hospital-based support programme could improve adherence to both pharmacological and non-pharmacological heart failure guidelines once patients transitioned back to primary care. This question addresses a well-documented implementation gap: evidence-based treatments for heart failure are underutilised in general practice, partly because primary care clinicians face practical barriers to initiating and titrating complex cardiac medication regimens and coordinating rehabilitation services.
How It Was Studied
The PATHFINDER trial was a randomised controlled trial enrolling 225 patients hospitalised with heart failure, allocated in a 1:1 ratio to either the intervention or usual care control group. The intervention comprised guideline-based inpatient education, a structured post-discharge plan that included referral to cardiac rehabilitation, scheduled general practitioner follow-up appointments at one week, four weeks, and three months post-discharge, and a cardiologist-approved medication titration plan to guide prescribing decisions in primary care. The control group received standard post-discharge care without these additional supports. The primary outcome was assessed at six months, and 25% of participants were female.
What Was Observed
- Overall guideline adherence was more than twice as high in the intervention group. Achieving the composite primary outcome — defined as adherence across five recommended treatments — occurred in 61.8% of intervention participants versus 28.7% of controls. This translates to roughly 6.3 times greater odds of achieving adherence in the intervention group (OR 6.27, 95% CI 3.35–11.76, p<0.01), a substantial and statistically highly significant difference.
- Medication prescribing rates drove much of the benefit. Higher rates of ACEI/ARB/ARNI prescriptions and beta-blocker prescriptions at or above 50% of target dose in the intervention group were identified as the principal contributors to the overall difference in composite adherence, indicating that the cardiologist-approved titration plan and structured GP follow-ups facilitated more complete pharmacological management.
- Cardiac rehabilitation referral was also significantly improved. Referral to cardiac rehabilitation — a non-pharmacological component of the composite outcome — was higher in the intervention group, demonstrating that the post-discharge plan successfully addressed both medication and rehabilitation components of guideline-recommended care.
Why This Matters
These findings provide direct evidence that the persistent underimplementation of heart failure guidelines in primary care is at least partly addressable through structured support originating at the point of hospitalisation. By embedding a titration plan and follow-up schedule into the discharge process, the intervention effectively bridged the communication gap between inpatient cardiology and outpatient general practice. If replicated at scale, this model of transitional care could meaningfully reduce the burden of under-treated heart failure and its associated risk of rehospitalisation and mortality.
How to Read This Result
While the effect size is large and the trial design is sound, confidence in these findings should remain moderate given the relatively small sample (N=225), the absence of reported longer-term follow-up beyond six months, and uncertainties about generalisability across different health systems or settings that may lack equivalent hospital-to-primary-care infrastructure.
Limitations
The abstract does not explicitly report study limitations.